S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

BMRN BioMarin Pharmaceutical Inc

69.005

0.755 (1.11%)

After Hours

Last Updated: 08:30:00

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more BioMarin Pharmaceutical Charts.

BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more BioMarin Pharmaceutical Charts.

BioMarin Pharmaceutical Inc News

Form 8-K - Current report
Tuesday 25 February 2025 (59 minutes ago) • Edgar (US Regulatory)

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
Tuesday 25 February 2025 (1 hour ago) • PR Newswire (US)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Tuesday 25 February 2025 (4 hours ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 25 February 2025 (7 hours ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 20 February 2025 (5 days ago) • Edgar (US Regulatory)

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
Thursday 20 February 2025 (5 days ago) • PR Newswire (US)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 14 February 2025 (2 weeks ago) • Edgar (US Regulatory)

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET
Thursday 6 February 2025 (3 weeks ago) • PR Newswire (US)

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
Tuesday 14 January 2025 (1 month ago) • PR Newswire (US)

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA
Tuesday 7 January 2025 (2 months ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 4 December 2024 (3 months ago) • Edgar (US Regulatory)

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
Sunday 17 November 2024 (3 months ago) • PR Newswire (US)

More BioMarin Pharmaceutical Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions